Stifel lowered the firm’s price target on Sage Therapeutics (SAGE) to $6 from $10 and keeps a Hold rating on the shares. 2024 was “a challenging year,” with shares down about 75% following the failure/discontinuation of SAGE-718, Stifel notes. Sage has “an arguably overqualified CEO” in Barry Greene who the firm thinks is committed to Sage and helping the company re-build itself, the analyst stated. It “seems plausible” that the next leg of investment could be via a combination of advancing internal programs and also business development, the latter being “a very logical step albeit one that is hard to predict or forecast,” the analyst added.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $9 from $10 at TD Cowen
- Sage Therapeutics price target lowered to $4 from $7 at BofA
- RBC upgrades Sage to Sector Perform with negative thesis played out
- Sage Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright